发明公开
EP2970482A1 TREATMENT OF CANCER USING HUMANIZED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR
审中-公开
TOR UNG ON ON TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR
- 专利标题： TREATMENT OF CANCER USING HUMANIZED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR
- 专利标题（中）： TOR UNG ON ON TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR
-
申请号： EP14722469.5申请日： 2014-03-15
-
公开(公告)号： EP2970482A1公开(公告)日： 2016-01-20
- 发明人: BROGDON, Jennifer , JUNE, Carl H. , LOEW, Andreas , MAUS, Marcela , SCHOLLER, John
- 申请人： Novartis AG , The Trustees of the University of Pennsylvania
- 申请人地址： Lichtstrasse 35 4056 Basel CH
- 专利权人： Novartis AG,The Trustees of the University of Pennsylvania
- 当前专利权人： Novartis AG,The Trustees of the University of Pennsylvania
- 当前专利权人地址： Lichtstrasse 35 4056 Basel CH
- 代理机构： Wilding, James Roger
- 优先权： US201361802629P 20130316; US201361838537P 20130624
- 国际公布： WO2014153270 20140925
- 主分类号： C07K16/28
- IPC分类号： C07K16/28 ; A61K35/14 ; C07K14/725 ; C07K14/705 ; C07K16/30 ; C12N5/0783 ; A61P35/00
摘要：
The invention provides compositions and methods for treating diseases associated with expression of CD19. The invention also relates to chimeric antigen receptor (CAR) specific to CD19, vectors encoding the same, and recombinant T cells comprising the CD19 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD19 binding domain.
公开/授权文献
信息查询
